Moderna says its coronavirus vaccine trial produced ‘robust’ immune response in all patients – CNBC

Moderna’s potential vaccine to prevent Covid-19 which was first reported to be appearing to be safe back in mid-May, offering a glint of hope, has just been reported by CNBC to have produced neutralizing antibodies in all 45 patients in its early stage human trial.

Key points

• Moderna’s potential vaccine to prevent Covid-19 produced neutralizing antibodies in all 45 patients in its early stage human trial, according to newly released data.
• The findings provide more promising data that the vaccine may give some protection against the coronavirus.

More to come...